India Pharma Outlook Team | Thursday, 19 November 2026
India's pharmaceutical manufacturing sector could face tighter regulatory requirements as the Union Health Ministry proposes stronger oversight of antimicrobial drugs.
The ministry has proposed amendments to the New Drugs and Clinical Trials Rules, 2019. The proposal aims to strengthen manufacturing approvals by requiring companies to secure Central regulatory permission before approaching state authorities for manufacturing licenses.
The move could make scientific assessments and quality checks more important for pharmaceutical manufacturers.
The proposed amendment seeks to include antimicrobials within the definition of a new drug under Rule 2(1)(w)(v) of the 2019 rules. This change would bring antimicrobial drug manufacturing under the Central regulatory framework applicable to new drugs.
Under the proposed system, manufacturers must obtain prior permission from the Central Licensing Authority (CLA) before applying to the respective State Licensing Authority (SLA) for manufacturing licenses.
The ministry has raised concerns about manufacturers securing licenses without adequate scientific and regulatory assessments. These include:
The proposed checks aim to ensure manufacturers meet essential quality, safety, and efficacy requirements before they begin production.
Also Read: India's Drug Pricing Architecture: Why the Rules Keep Expanding
The ministry has warned that inadequate scrutiny could affect the quality and effectiveness of antimicrobial products. Substandard or ineffective medicines can contribute to antimicrobial resistance, making infections harder to treat and creating additional risks for patients.
For pharmaceutical manufacturers, the proposal could bring greater attention to:
Therefore, this proposal also supports India's broader efforts to address AMR through a coordinated One Health approach, which recognizes the connection between human, animal and environmental health. Stronger manufacturing oversight could therefore become an important step towards improving antimicrobial drug quality and protecting public health.